Dexmedetomidine Continuous Infusion for Refractory Cancer Pain at End of Life: A Case Report

References

• Fainsinger RL, Nekolaichuk CL. A "TNM" classification system for cancer pain: the edmonton classification system for cancer pain (ECS-CP). Support Care Cancer. 2008;16(6):547–55. doi:10.1007/s00520-008-0423-3.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network® (NCCN®). 2022. Available from: https://www.nccn.org/docs/default-source/oncology-policy-program/2019_nccn-response-ahrq-request-for-evidence-dyspnea.pdf?sfvrsn=556b4bd1_2.
   Google Scholar
• Tagami K, Matsuoka H, Ariyoshi K, Oyamada S, Hiratsuka Y, Kizawa Y, Koyama A, Inoue A. The current clinical use of adjuvant analgesics for refractory cancer pain in Japan: a nationwide cross-sectional survey. Jpn J Clin Oncol. 2020;50(12):1434–41. doi:10.1093/jjco/hyaa147.
   PubMedGoogle Scholar
• Siler S, Borneman T, Ferrell B. Pain and suffering. Semin Oncol Nurs. 2019;35(3):310–4. doi:10.1016/j.soncn.2019.04.013.
   PubMedGoogle Scholar
• Strang P. Cancer pain–a provoker of emotional, social and existential distress. Acta Oncol. 1998;37(7-8):641–4. doi:10.1080/028418698429973.
   PubMed Web of Science ®Google Scholar
• Martin CM, Forrester CS. Anticipating and managing opioid side effects in the elderly. Consult Pharm. 2013;28(3):150–9. doi:10.4140/TCP.n.2013.150.
   PubMedGoogle Scholar
• Yoon SY, Oh J. Neuropathic cancer pain: prevalence, pathophysiology, and management. Korean J Intern Med. 2018;33(6):1058–69. doi:10.3904/kjim.2018.162.
   PubMed Web of Science ®Google Scholar
• Atayee RS, Hur GH, Karimian P, Hollenbach KA, Edmonds KP. Methadone inpatient and discharge prescribing patterns for pain at an academic health system. J Palliat Med. 2017;20(2):184–92. doi:10.1089/jpm.2016.0267.
   PubMedGoogle Scholar
• Karimian P, Atayee RS, Ajayi TA, Edmonds KP. Methadone dose selection for treatment of pain compared with consensus recommendations. J Palliat Med. 2017;20(12):1385–8. doi:10.1089/jpm.2017.0089.
   PubMed Web of Science ®Google Scholar
• Tran K, McCormack S. Ketamine for chronic non-cancer pain: a review of clinical effectiveness, cost-effectiveness, and guidelines. CADTH rapid response reports. 2020.
   Google Scholar
• Hakim RC, Edmonds KP, Atayee RS. Case report: utility of ketamine, lidocaine, and mexiletine as nonopioid adjuvants in complex cancer-associated pain. J Pain Palliat Care Pharmacother. 2018;32(1):15–9. doi:10.1080/15360288.2018.1463345.
   PubMed Web of Science ®Google Scholar
• Atayee RS, Naidu D, Geiger-Hayes J, Saphire ML, Hausdorff J, Edmonds KP. A multi-centered case series highlighting the clinical use and dosing of lidocaine and mexiletine for refractory cancer pain. J Pain Palliat Care Pharmacother. 2020;34(2):90–8. doi:10.1080/15360288.2019.1704339.
   PubMed Web of Science ®Google Scholar
• Gaertner J, Fusi-Schmidhauser T. Dexmedetomidine: a magic bullet on its way into palliative care-a narrative review and practice recommendations. Ann Palliat Med. 2022;11(4):1491–504. doi:10.21037/apm-21-1989.
   PubMed Web of Science ®Google Scholar
• Hilliard N, Brown S, Mitchinson S. A case report of dexmedetomidine used to treat intractable pain and delirium in a tertiary palliative care unit. Palliat Med. 2015;29(3):278–81. doi:10.1177/0269216314556923.
   PubMed Web of Science ®Google Scholar
• Tang C, Xia Z. Dexmedetomidine in perioperative acute pain management: a non-opioid adjuvant analgesic. J Pain Res. 2017;10:1899–904. doi:10.2147/JPR.S139387.
   PubMed Web of Science ®Google Scholar
• Burns J, Jackson K, Sheehy KA, Finkel JC, Quezado ZM. The use of dexmedetomidine in pediatric palliative care: a preliminary study. J Palliat Med. 2017;20(7):779–83. doi:10.1089/jpm.2016.0419.
   PubMedGoogle Scholar
• Seymore RJ, Manis MM, Coyne PJ. Dexmedetomidine use in a case of severe cancer pain. J Pain Palliat Care Pharmacother. 2019;33(1-2):34–41. doi:10.1080/15360288.2019.1629520.
   PubMedGoogle Scholar
• Ferguson L, Wilson M. Intranasal dexmedetomidine: procedural sedation in palliative care: a case report. Palliat Med. 2021;35(8):1625–8. doi:10.1177/02692163211022184.
   PubMedGoogle Scholar
• Coyne PJ, Wozencraft CP, Roberts SB, Bobb B, Smith TJ. Dexmedetomidine: exploring its potential role and dosing guideline for its use in intractable pain in the palliative care setting. J Pain Palliat Care Pharmacother. 2010;24(4):384–6. doi:10.3109/15360288.2010.518227.
   PubMedGoogle Scholar
• Hofherr ML, Abrahm JL, Rickerson E. Dexmedetomidine: a novel strategy for patients with intractable pain, opioid-induced hyperalgesia, or delirium at the end of life. J Palliat Med. 2020;23(11):1515–7. doi:10.1089/jpm.2019.0427.
   PubMed Web of Science ®Google Scholar
• Prommer E. Review article: dexmedetomidine: does it have potential in palliative medicine? Am J Hosp Palliat Care. 2011;28(4):276–83. doi:10.1177/1049909110389804.
   PubMed Web of Science ®Google Scholar
• Roberts SB, Wozencraft CP, Coyne PJ, Smith TJ. Dexmedetomidine as an adjuvant analgesic for intractable cancer pain. J Palliat Med. 2011;14(3):371–3. doi:10.1089/jpm.2010.0235.
   PubMed Web of Science ®Google Scholar
• Savelloni J, Gunter H, Lee KC, Hsu C, Yi C, Edmonds KP, Furnish T, Atayee RS. Risk of respiratory depression with opioids and concomitant gabapentinoids. J Pain Res. 2017;10:2635–41. doi:10.2147/JPR.S144963.
   PubMed Web of Science ®Google Scholar
• Kwon JH, Tanco K, Hui D, Reddy A, Bruera E. Chemical coping versus pseudoaddiction in patients with cancer pain. Palliat Support Care. 2014;12(5):413–7. doi:10.1017/S1478951513001351.
   PubMedGoogle Scholar
• Chlorpromazine hydrochloride package insert. 2022. Available from: https://genesight.com/wp-content/uploads/2017/05/Chlorpromazine-Thorazine-FDA-Label.pdf.
   Google Scholar
• Mupamombe CT, Luczkiewicz D, Kerr C. Dexmedetomidine as an option for opioid refractory pain in the hospice setting. J Palliat Med. 2019;22(11):1478–81. doi:10.1089/jpm.2019.0035.
   PubMed Web of Science ®Google Scholar
• Yoo H, Iirola T, Vilo S, Manner T, Aantaa R, Lahtinen M, Scheinin M, Olkkola KT, Jusko WJ. Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects. Eur J Clin Pharmacol. 2015;71(10):1197–207. doi:10.1007/s00228-015-1913-0.
   PubMed Web of Science ®Google Scholar
• Dexmedetomidine hydrochloride package insert. 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206628s000lbl.pdf.
   Google Scholar
• De Wolf AM, Fragen RJ, Avram MJ, Fitzgerald PC, Rahimi-Danesh F. The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment. Anesth Analg. 2001;93(5):1205–9. doi:10.1097/00000539-200111000-00031.
   PubMed Web of Science ®Google Scholar
• Song J-C, Gao H, Qiu H-B, Chen Q-B, Cai M-H, Zhang M-Z, Lu Z-J. The pharmacokinetics of dexmedetomidine in patients with obstructive jaundice: A clinical trial. PLoS One. 2018;13(11):e0207427. doi:10.1371/journal.pone.0207427.
   PubMedGoogle Scholar
• Kim J, Kim WO, Kim HB, Kil HK. Adequate sedation with single-dose dexmedetomidine in patients undergoing transurethral resection of the prostate with spinal anaesthesia: a dose-response study by age group. BMC Anesthesiol. 2015;15:17. doi:10.1186/1471-2253-15-17.
   PubMed Web of Science ®Google Scholar
• Thomas B, Lo WA, Nangati Z, Barclay G. Dexmedetomidine for hyperactive delirium at the end of life: An open-label single arm pilot study with dose escalation in adult patients admitted to an inpatient palliative care unit. Palliat Med. 2021;35(4):729–37. doi:10.1177/0269216321994440.
   PubMed Web of Science ®Google Scholar
• Thomas B, Murrell L, Spendley P. Dexmedetomidine: admixture compatibility with palliative care drugs. BMJ Support Palliat Care. 2021:1–2. doi:10.1136/bmjspcare-2020-002583.
   Google Scholar